Form 8-K - Current report:
SEC Accession No. 0001104659-25-009387
Filing Date
2025-02-05
Accepted
2025-02-05 08:08:10
Documents
14
Period of Report
2025-02-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255497d2_8k.htm   iXBRL 8-K 26075
2 EXHIBIT 99.1 tm255497d2_ex99-1.htm EX-99.1 11303
  Complete submission text file 0001104659-25-009387.txt   216881

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20250205.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20250205_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20250205_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT tm255497d2_8k_htm.xml XML 3791
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 25590963
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)